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Abstract 
 
 It has been reported that lifestyle including diet is associated with Alzheimer’s 
disease (AD) risk and progression. Population studies indicate that the chronic 
consumption of diets enriched in saturated fats (SFA) and cholesterol significantly 
increase the risk of AD onset and progression. However, the mechanisms underlying the 
association of AD risk with dietary fat intake are presently unclear 
  
Proteinaceous deposits enriched in amyloid-β (Aβ) within the cerebral 
parenchyma (amyloid plaque) and in the cerebrovasculature (cerebral amyloid 
angiopathy) are the hallmark pathological features of AD. Several animal and cell 
culture studies suggest that high-fat diets exacerbate amyloidosis by promoting Aβ 
secretion by neurons and increasing the propensity for oligomerization to occur.  
However, there is little evidence consistent with cerebral Aβ overproduction in AD. 
Rather, recent studies in animal models of AD suggest that efflux of Aβ relative to its 
delivery from the blood is pivotal to cerebral Aβ homeostasis.  
 
 Two lines of evidence led me to develop the hypothesis that dietary fats may 
influence AD risk by modulating cerebrovascular exposure to circulating Aβ (Paper1 
presented as Literature review of thesis). Firstly, Aβ has potent vasoactive properties 
and blood vessels treated with exogenous Aβ show substantial structural damage. 
Moreover, exaggerated plasma Aβ could occur because of chronic ingestion of diets 
enriched in fats. Dietary SFA were found to significantly increase Aβ abundance within 
the absorptive cells of small intestine (enterocytes) and thereafter, substantial plasma 
Aβ remains associated with triglyceride rich lipoproteins (TRLs). It is my contention 
that cerebrovascular integrity is compromised by the ingestion of fats which increases 
the plasma concentration of Aβ. 
 
 An immunohistochemical approach was developed to explore the effects of 
dietary SFA and cholesterol on cerebrovascular integrity and Aβ kinetics at the blood-
brain barrier (BBB) (Paper 2 presented as Chapter 2 of thesis). Wild-type (WT) mice 
were used for the dietary intervention studies and appropriate comparisons were made 
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with amyloid precursor protein/presenilin-1 (APP/PS1) amyloid transgenic mice, an 
established model of AD (Paper 3-5 presented as Chapters 3-5). Critical to the primary 
scientific objectives, three-dimensional colocalization analysis using double 
immunofluorescent microscopy was developed (Paper 2). This double 
immunofluorescent labelling technique enabled the simultaneous detection of two 
proteins utilizing polyclonal antibodies derived from the same species. Briefly, in order 
to avoid the cross-reactivity of two polyclonal antibodies that originate from the same 
species, the concentration of one of the primary antibodies was reduced, so that it was 
undetectable with conventional secondary antibody methodologies. Rather, avidin-
biotin amplification that was specific for the diluted primary antibody was utilized to 
identify its specific immunoreactivity. The double labelling of proteins with certainty 
that cross-reactivity did not occur, enabled consideration of protein distribution and 
association within tissues and cells.   
 
 In some cells Aβ is generated following processing of a precursor protein (APP) 
embedded within the plasma membrane. However, Chapter 5 of this thesis (Paper 5) 
shows that within enterocytes of the upper small intestine, Aβ genesis occurs within the 
Golgi apparatus and is likely secreted associated with nascent postprandial lipoproteins 
(chylomicrons). Apolipoprotein B immunoreactivity was used as a surrogate marker of 
enterocytic chylomicron distribution as it is an obligatory component of these 
macromolecules.  
 
 Evidence that plasma derived apo B lipoproteins containing Aβ may contribute 
to the aetiology of AD is presented in Chapter 3 (Paper 3). Consistent with the 
hypothesis presented, APP/PS1 mice were previously reported to have significantly 
increased secretion of TRL-Aβ as a consequence of the genetically induced over-
expression of Aβ. However, this study expanded on that finding and explored if there 
was evidence of blood-to-brain delivery of apo B and if this was positively associated 
with amyloid plaque distribution and abundance. In transgenic APP/PS1 mice, 
immunoreactive apo B was detected in the core and periphery of cerebral amyloid 
plaques with significant colocalization coefficience (Manders’ overlap coefficient = 
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0.85±0.004). The findings are consistent with the notion that cerebrovascular exposure 
to plasma TRL-Aβ is causally associated with cerebral amyloidosis. 
 
 Chapter 4 (Paper 4) investigates the differential effects of dietary fatty acids on 
BBB integrity. WT mice were fed either low-fat (LF) control chow, or physiologically 
relevant diets enriched in SFA, monounsaturated fatty acid (MUFA) or polyunsaturated 
fatty acid (PUFA) for either 3 or 6 months. Blood-to-brain delivery of apo B was found 
in SFA fed mice and exaggerated with a longer duration of feeding. The distribution of 
cerebral apo B in SFA fed mice, closely paralleled with the distribution of Aβ, 
consistent with blood-to-brain delivery as a lipoprotein complex. The cerebral 
extravasation of apo B was more evident in the cortex region (CTX) than in 
hippocampal formation (HPF). Mice fed the LF control, MUFA or PUFA diets for 3 or 
6 months showed no evidence of apo B/Aβ parenchymal extravasation. The cerebral 
distribution of immunoglobulin G (IgG) was used as a surrogate marker of non-specific 
plasma protein leakage into the brain. In SFA fed mice alone, significant peri-vascular 
leakage of IgG was observed, suggesting that the endothelial dysfunction induced by 
SFA feeding was a non-specific or leakage phenomenon. Consistent with the latter, 
plasma S100B, a marker of brain-to-blood protein kinetics, was significantly increased 
in SFA fed mice but not in LF control, MUFA or PUFA supplemented mice. SFA group 
mice also had significantly attenuated occludin-1 expression, the primary BBB 
endothelial tight junction protein. Apo B and IgG extravasation greater in CTX than in 
HPF, increased plasma S100B, and decreased occludin-1 abundance were also observed 
in APP/PS1 amyloid transgenic mice. Hence the findings in SFA fed mice are 
consistent with a causal role in cerebral amyloidosis. 
 
 The data presented in this thesis and consideration of other studies reported 
particularly since commencement of my candidacy are then presented in Chapter 5, 
which was published as a review in Progress in Lipid Research (Paper 5). Briefly, 
several studies suggest that significant plasma Aβ is associated with TRLs secreted by 
the small intestine as chylomicrons and from the liver as very low density lipoproteins. 
Evidence presented in this thesis of apo B colocalization within amyloid plaques is 
consistent with the concept that plasma derived lipoprotein-Aβ may be causally 
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associated with cerebral amyloidosis. However, for delivery of lipoprotein-Aβ from 
blood to brain to occur, the breakdown of BBB function would be required as the 
cerebrovasculature architecture normally prevents transport of large macromolecules 
such as lipoproteins. In this study, chronic consumption by WT mice of food enriched 
in SFA resulted in non-specific leakage of plasma proteins within the brain parenchyma, 
analogous to that observed in an established transgenic murine model of AD (APP/PS1 
mice). Within the review, dietary cholesterol is shown to elicit the same response. The 
mechanisms by which SFA and cholesterol cause the BBB dysfunction are presently 
unclear. Increased BBB exposure to circulating TRL-Aβ is one possibility, however, 
there was no significant difference in fasting plasma Aβ in mice maintained on SFA or 
cholesterol supplemented diets compared to LF control. Postprandial transient increases 
in plasma TRL-Aβ, not necessarily detected in fasting blood, may have been sufficient 
to cause the BBB dysfunction, but this was not specifically investigated. Alternatively 
SFA and cholesterol may have compromised cerebrovascular integrity via Aβ 
independent mechanisms, many of which are considered in depth in the review article. 
The review manuscript also discusses the potential mechanisms that could contribute to 
the extracellular retention of apo B lipoproteins enriched in Aβ and the inflammatory 
sequelae that may ensue thereafter. There is a positive association of apo B/Aβ retention 
with the abundance of the heparin-sulphate proteoglycans; perlecan, biglycan and 
decorin. A number of studies show that apo B lipoproteins are avidly metabolized by 
inflammatory cells and indeed under certain conditions may trigger the inflammatory 
cascade. In the review article, this paradigm is discussed in the context of apo B 
lipoproteins containing Aβ and putative interaction with activated glial cells.  
  
 Collectively, the results presented in this thesis suggest that dietary SFA and 
cholesterol may increase the risk of AD and/or accelerate the progression of disease by 
compromising cerebrovascular integrity and promoting the cerebral delivery of Aβ from 
the blood. The findings support the contention that diet is an important consideration in 
the context of disease prevention, but also raise the intriguing notion that nutritional 
intervention approaches could be developed to treat AD.  
vii 
List of Publications Included 
 
This thesis contains the following 5 peer-reviewed scientific publications. These articles 
have been published or accepted for publication in quality scientific journals. Signed 
declarations of the contributions of coauthors are provided as Appendix A (pages 87-
100). 
 
1. Takechi R, Galloway S, Pallebage-Gamarallage MM, Wellington C, Mamo JC. 
(2008) Chylomicron β-amyloid in the aetiology of Alzheimer’s disease. 
Atheroscler Suppl. 9, 19-25 [Impact factor: 6.6] 
2. Takechi R, Galloway S, Pallebage-Gamarallage MM, Johnsen RD, Mamo JC. 
(2008) Three-dimensional immunofluorescent double-labelling using 
polyclonal antibodies derived from the same species: Enterocytic 
colocalization of chylomicrons with Golgi apparatus. Histochem Cell Biol. 129, 
779-84 [Impact factor: 2.3] 
3. Takechi R, Galloway S, Pallebage-Gamarallage MM, Wellington C, Johnsen R, 
Mamo JC. (2009) Three-dimensional colocalization analysis of plasma-derived 
apolipoprotein B with amyloid plaques in APP/PS1 transgenic mice. 
Histochem Cell Biol. 131, 661-6 [Impact factor: 2.3] 
4. Takechi R, Galloway S, Pallebage-Gamarallage MM, Wellington CL, Johnsen RD, 
Dhaliwal SS, Mamo JC. (2009) Differential effects of dietary fatty acids on the 
cerebral distribution of plasma derived apo B lipoproteins with amyloid-β. Br J 
Nutr. (in press) [Impact factor: 2.8] 
5. Takechi R, Galloway S, Pallebage-Gamarallage MMS, Lam V, Mamo JCL. (2009) 
Dietary fats, cerebrovascular integrity and Alzheimer’s disease risk. Prog Lipid 
Res. (in press)  [Impact factor: 11.2] 
viii 
List of Additional Publications 
 
2 additional papers that compliment but are not considered central to the hypothesis 
presented in this thesis are listed and provided as Appendix B (pages 101-118). 
 
1. Galloway S, Pallebage-Gamarallage MM, Takechi R, Jian L, Johnsen RD, 
Dhaliwal SS, Mamo JC. (2008) Synergistic effects of high fat feeding and 
apolipoprotein E deletion on enterocytic amyloid β abundance. Lipids Health 
Dis. 7, 15 [Impact factor: 2.1] 
2. Galloway S, Takechi R, Pallebage-Gamarallage MM, Dhaliwal SS, Mamo JC. 
(2009) Amyloid-β colocalizes with apolipoprotein B in absorptive cells of the 
small intestine. Lipids Health Dis. 8, 46 [Impact factor: 2.1] 
 
ix 
Introduction and Structure of Thesis 
 
Introduction 
 
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder 
resulting in the progressive decline of cognitive and physical functions. It has been 
almost a century since the first case of AD was diagnosed by the German psychiatrist 
and neuropathologist, Alois Alzheimer. However the aetiology of AD is still unclear 
and the disease remains incurable. Currently 25 million individuals have been 
diagnosed with AD and the number is estimated to double within the next 20 years 
(2008; Bickel 2001; Brookmeyer et al. 2007). In Australia, approximately 1% of the 
population have dementia primarily as AD  and this is predicted to increase to 3% by 
2050. Within the next decade, dementia will be the major cause of disability in 
Australia, greater than either cancer or cardiovascular disease. By 2030 the economic 
health burden for dementia will be approximately $9.5 billion p.a., exceeding the 
treatment of cancers by 30% and equivalent to the combined costs for the prevention 
and treatment of cardiovascular disease. Clearly, the development of prevention and 
treatment strategies for AD are urgently required. 
 
A hallmark pathological feature of AD is the abnormal accumulation of 
amyloid-β (Aβ) peptide in the cerebral parenchyma (amyloid plaque) and in the 
cerebrovasculature (cerebral amyloid angiopathy) (Joachim et al. 1988a; Joachim et al. 
1988b). The aggregation and fibrillar formation of Aβ forms an insoluble neurotoxic 
aggregate (plaque) that may trigger inflammatory sequelae including neuronal cell death. 
However, the origin of Aβ found in cerebral amyloidosis is controversial. Aβ is derived 
from the enzymatic cleavage of a precursor protein (amyloid-precursor-protein or APP) 
(Joachim et al. 1988a). Neurons produce Aβ and several genes related to increased 
neuronal Aβ biogenesis have been reported in familial AD (Citron et al. 1997; Hardy 
and Higgins 1992; Kirkitadze and Kowalska 2005; Tomita et al. 1998). However, 
presently there is little evidence that Aβ synthesis is increased in sporadic and late onset 
AD, the most common form of this disorder (Cummings et al. 1998). Rather, an 
insufficient Aβ clearance across the blood-brain barrier (BBB) via receptor pathways 
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and/or via the choroid plexus has been suggested as an alternative pathway for 
amyloidosis (Crossgrove et al. 2005; Deane et al. 2009; Deane et al. 2005). Moreover, 
recent evidence that Aβ may also be delivered from blood-to-brain could conceivably 
exacerbate the parenchymal load in the absence of compensatory clearance pathways 
(Donahue et al. 2006). 
 
The BBB is characterized by endothelial cells of the cerebrovasculature and 
basement membranes of the lamina rara externa, lamina densa, and lamina rara interna 
that are tightly apposed (Farkas and Luiten 2001). The properties of the BBB enable the 
brain vascular endothelium to exclude neurotoxic and inflammatory agents such as 
proteins, ions, non-electrolytes and water, and to allow for the highly selective 
exchange of substances between the systemic circulation and the interstitial fluid of the 
brain (Deane et al. 2003; Donahue et al. 2006; Maness et al. 1994; Martel et al. 1996; 
Zlokovic et al. 1993). In AD subjects, pathological alterations of the cerebrovasculature 
including vascular endothelial and smooth muscle cell proliferation are often reported 
(Ellis et al. 1996). Plasma derived proteins have been detected in the parenchyma of AD 
brains (Kalaria 1992; Wisniewski et al. 1997), and inflammatory sequelae are 
commonly reported (Cullen 1997; Itagaki et al. 1989), observations consistent with 
breakdown of the BBB. Yet despite evidence supportive of AD having an underlying 
vascular component, most research focuses on damage of neurons.
 
Recent studies have suggested that lifestyle including nutrition is associated with 
AD risk, age of onset and disease progression (Abbott et al. 2004; Kivipelto and 
Solomon 2008; Larson et al. 2006; Pasinetti and Eberstein 2008; Podewils et al. 2005; 
Santana-Sosa et al. 2008; van Gelder et al. 2004; Weuve et al. 2004). Based on 
population and animal studies, high-fat diets that are characterized by significant 
quantities of saturated fats (SFA) and cholesterol are a risk factor of AD (Engelhart et al. 
2002; Kalmijn 2000; Laitinen et al. 2006; Luchsinger and Mayeux 2004; Morris et al. 
2003; Oksman et al. 2006; Refolo et al. 2000; Shie et al. 2002; Solfrizzi et al. 2005; 
Solfrizzi et al. 2009; Sparks et al. 1994). In contrast, diets enriched in polyunsaturated 
fats, particularly the omega 3 oils, may confer protection against AD risk, age of onset 
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and progression (Cole and Frautschy 2006; Hooijmans et al. 2007; Hooijmans et al. 
2009; Lim et al. 2005; Oksman et al. 2006; Schaefer et al. 2006).  
 
 The mechanisms by which dietary fats influence AD risk were the stimulus for 
my PhD candidacy. One commonly held view is that diets enriched in cholesterol 
stimulate Aβ biogenesis in the brain resulting in the abnormal accumulation of Aβ 
peptides. However, paradoxical studies in cell culture models suggest that cholesterol 
may be both stimulatory and inhibitory (Abad-Rodriguez et al. 2004; Frears et al. 1999), 
and there is no evidence of cerebral Aβ overproduction per se in AD (Cummings et al. 
1998).  
 
In blood, plasma Aβ can be derived from vascular smooth muscle cells and 
endothelial cells, or from blood platelets. However, another significant source of plasma 
Aβ may be from lipogenic organs such as the small intestine and liver (Biere et al. 
1996; Koudinov and Koudinova 1997; Mamo et al. 2008). Hepatocytes and absorptive 
epithelial cells of the small intestine (enterocytes) secrete Aβ as a lipoprotein complex, 
and in the small intestine this pathway is under dietary fat regulation (Boyt et al. 1999; 
Galloway et al. 2007; Galloway et al. 2008; James et al. 2003; Pallebage-Gamarallage 
et al. 2009; Takechi et al. 2008a; Takechi et al. 2008b). Chronic ingestion of SFA was 
reported to significantly enhance enterocytic abundance of Aβ and conversely the 
protein could not be detected when animals were fasted (Galloway et al. 2007). 
Distributional analysis of plasma lipoprotein-Aβ in normal and AD subjects found that 
greater than 60% of plasma-lipoprotein-Aβ was associated with triglyceride-rich 
liporpteins (TRLs) and this was significantly increased in those with AD or subjects 
with mild-cognitive-impairment (Mamo et al. 2008). Whilst AD subjects are typically 
normolipidemic, the concentration of apolipoprotein (apo) B48 (an exclusive marker of 
chylomicrons) was elevated more than 3-fold in post-absorptive AD subjects (Mamo et 
al. 2008). Increased apo B48 is indicative of post-prandial dyslipidemia, an exaggerated 
rise in plasma chylomicrons that occurs following the ingestion of dietary fats. 
Consistent with the notion of an Aβ post-prandial response, ingestion of a lipid enriched 
meal was found to cause a transient increase in the plasma concentration of the APP and 
of Aβ in otherwise healthy subjects (James et al. 2003). 
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The mechanisms by which circulating Aβ could increase the risk of AD are 
presently unclear. However, several studies have provided evidence of a vasoactive role 
of Aβ with pathological manifestations prior to Aβ deposition (George et al. 2004; 
Thomas et al. 1997). Amyloid-β is vasoconstrictive and vessels treated with exogenous 
Aβ show significant endothelial cell damage with changes in the cell membrane, 
cytoplasm, nucleus and other organelles. In previous studies, significant breakdown of 
the BBB was reported following acute or chronic intravenous injection of Aβ. 
 
 
Hypothesis 
 
The broad hypothesis on which my candidacy is based is that dietary SFA and 
cholesterol compromise BBB function because of exaggerated exposure to plasma 
lipoprotein-Aβ. As a consequence of these specific dietary induced cerebrovascular 
aberrations, rates of lipoprotein-Aβ delivery from blood to brain are exaggerated. 
Lipoproteins endogenously enriched in Aβ then become retained on extracellular 
matrices initiating an inflammatory response.  
 
 
Objectives 
 
This thesis puts forward an innovative perspective of the putative mechanisms 
underlying the link between dietary fats and AD risk. The primary objective of this 
study was to investigate the effects of chronic ingestion of different fatty acids on the 
integrity of the BBB in a wild-type (WT) mouse model fed either low-fat (LF) control, 
SFA, monounsaturated fats (MUFA) or polyunsaturated fats (PUFA). A response to 
duration model was utilized exploring the putative effects at 3 and 6 months of feeding 
and comparisons were made with amyloid transgenic mice that are commonly used as a 
model of AD pathology. The integrity of the BBB was investigated by determining 
whether plasma proteins were present within the brain parenchyma. The approach 
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utilized for this objective was state-of-art 3-dimensional (3-D) immunofluorescent 
microscopy developed as part of my candidacy and selected biochemical markers.  
 
The specific objectives of my candidacy were: 
Objective 1: To develop 3-dimensional double immunofluoroscent microscopy using 
polyclonal antibodies raised in the same species 
 
Objective 2: To establish 3-dimensional semi-quantitative colocalization analysis 
methodologies with double immunofluorescent labelling 
 
Objective 3: To investigate the 3-dimensional localization of plasma derived TRL-Aβ 
relative to cerebral amyloid plaque abundance  
 
Objective 4: To evaluate the differential effects of dietary fatty acids on BBB integrity 
in wild-type mice and to compare this with an established murine model 
of AD (amyloid transgenic mice) 
 
Objective 5: To provide informative consideration of whether disturbances in 
cerebrovascular integrity explain in part the positive association between 
dietary SFA/cholesterol ingestion and AD risk 
 
 
Structure of Thesis 
 
 This thesis consists of 5 peer-reviewed papers that have been published or 
accepted for publication. The first paper is a review article essentially summarising the 
literature at the commencement of my PhD which led to the genesis of the hypothesis 
presented. The second published manuscript is a methods paper describing the key 
approach used to investigate Aβ metabolism and cerebrovascular integrity by 
immunomicroscopy. Paper 3 reports the colocalization of apo B with cerebral amyloid 
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plaque in an established murine model of AD and provides direct evidence that 
circulating TRL-Aβ may contribute to the formation of amyloid plaques. The possibility 
that dietary fats modulate cerebrovascular integrity and blood-to-brain kinetics of 
plasma derived TRL-Aβ is reported in Paper 4. This particular study showed that 
chronic ingestion of SFA induced significant breakdown of the BBB and delivery from 
blood to brain of plasma derived apo B lipoprotein-Aβ, whereas MUFA and PUFA had 
no detrimental effects. The fifth manuscript which serves as the general discussion of 
my thesis presented additional studies which show that dietary cholesterol induces 
analogous disturbances as SFA on BBB function and apo B/Aβ kinetics across the BBB. 
The review also shows for the first time, retention of apo B lipoprotein containing Aβ 
with specific heparin sulphate proteoglycans. Possible mechanisms by which SFA and 
dietary cholesterol cause endothelial dysfunction are discussed in detail and take into 
consideration a significant number of relevant studies. 
 
 
Chapter 1 – Introduction and literature review 
 
The content of this chapter is covered by Paper 1:  
Takechi R, Galloway S, Pallebage-Gamarallage MM, Wellington C, Mamo JC. (2008) 
Chylomicron β-amyloid in the aetiology of Alzheimer’s disease. Atheroscler Suppl. 9, 
19-25 
 
 Chapter 1 is an introduction and literature review of the association between 
dietary fats and AD aetiology. Key papers from clinical, population, cell culture and 
animal studies are reviewed synthesizing the key elements which underpin the 
hypothesis and the objectives of the study. 
 
It is suggested that dietary SFA increases the risk of progression of AD. However the 
mechanisms for this association are presently unclear. This review takes into 
consideration the findings that SFA enhance enterocytic abundance of Aβ and by 
extension may increase the concentration of plasma Aβ. The latter may challenge 
cerebrovascular integrity resulting in a shift from blood to brain of circulating Aβ. The 
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putative SFA induced elevations in plasma Aβ may exacerbate or indeed trigger the 
amyloidogenic cascade. Other key published findings which led to the hypothesis were 
clinical studies which have revealed that significant plasma Aβ is associated with TRL 
particles, and the plasma TRL-Aβ level is elevated after a fat meal intake. 
 
  
Chapter 2 – Development of 3-dimensional double immunofluorescent 
labelling and semi-quantitative colocalization analysis methodology  
 
The content of this chapter is covered by Paper 2:  
Takechi R, Galloway S, Pallebage-Gamarallage MM, Johnsen RD, Mamo JC. (2008) 
Three-dimensional immunofluorescent double-labelling using polyclonal antibodies 
derived from the same species: Enterocytic colocalization of chylomicrons with Golgi 
apparatus. Histochem Cell Biol. 129, 779-84 
 
Thesis objectives addressed in this chapter: 
Objective 1: To develop 3-dimensional double immunofluoroscent microscopy using 
polyclonal antibodies raised in the same species 
 
Objective 2: To establish 3-dimensional semi-quantitative colocalization analysis 
methodologies with double immunofluorescent labelling 
 
 In this chapter, key methodologies pivotal to the scientific approach chosen to 
interrogate the Hypothesis that dietary SFA compromises BBB integrity resulting in 
blood-to-brain delivery of Aβ were established. A highly specific immunofluorescent 
double labelling method using polyclonal antibodies derived from the same species was 
demonstrated, and 3-D semi-quantitative colocalization analysis was developed. 
 
 Multiple labelling immunofluorescent microscopy has been used to consider the 
abundance and distribution of two or more proteins within cells and tissues. Briefly, the 
method ordinarily involves incubation of cells with two or more antibodies that will 
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only recognize highly conserved amino acid sequences of specific proteins (antigen). 
Following a washing procedure to remove excess primary antibodies not bound to 
antigen, the distribution of the respective primary antibody-antigen complexes are 
identified by incubating with secondary antibodies that bind exclusively to one of the 
primary antibodies. Visualisation of the two proteins is possible because the secondary 
antibodies are differentially conjugated to fluorochromes. In order to avoid cross 
reactivity between secondary antibodies and primary antibodies, the primary antibodies 
are normally derived from two alternate species. However, commercially available 
antibodies for the proteins of interest in this study were found to be in most instances 
limited to just one species (rabbit). In order to meet the objective of exploring 
associations in protein distribution and abundance, methods had to be developed to 
avoid cross-reactivity of the secondary antibodies with the primary antibodies. The 
approach developed required a dilution of one of the primary antibodies so that it could 
not be detected by conventional incubation with conjugated secondary antibodies. 
Rather, for the diluted primary antibody, the fluorescent emission following interaction 
with its specific secondary antibody had to be amplified utilizing an amplifying protocol 
(biotin-avidin). Critically, the biotin-avidin amplification process is specific for the 
diluted primary antibody interaction. The successful development of this technique was 
published in a highly ranked immunohistochemistry journal. To demonstrate the 
methodology, the manuscript reported on the colocalization of apo B and Golgi 
apparatus within enterocytes of the small intestine. The primary antibodies for apo B 
and Golgi were both derived from rabbits.  
 
 A second important methodological approach for this study was to develop 
measures of protein abundance (i.e. proportional to fluorescent intensity) and 
distribution in three dimensions. The published manuscript demonstrates the application 
of newly released microscopy hardware and software configuration (Zeiss’s ApoTome 
optical sectioning technologies and AxioVision image analysis software) and shows in 
3-D the colocalization of apo B within the enterocytic Golgi apparatus.  
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Chapter 3 – Colocalization of apolipoprotein B with cerebral amyloid 
plaques of Alzheimer’s disease 
 
The content of this chapter is covered by Paper 3:  
Takechi R, Galloway S, Pallebage-Gamarallage MM, Wellington C, Johnsen R, Mamo 
JC. (2009) Three-dimensional colocalization analysis of plasma-derived apolipoprotein 
B with amyloid plaques in APP/PS1 transgenic mice. Histochem Cell Biol. 131, 661-6 
 
Thesis objective addressed in this chapter: 
Objective 3: To investigate the 3-dimensional localization of plasma derived TRL-Aβ 
relative to cerebral amyloid plaque abundance 
 
 In this chapter, the 3-D colocalization of plasma derived TRL-Aβ and the 
amyloid plaques of the transgenic AD mouse model was demonstrated. 
 
The formation of amyloid plaques in the parenchyma of the brain is a hallmark 
feature of AD, however, the origin of Aβ is still unclear. Several lines of evidence 
suggest that the plasma concentration of Aβ is positively associated with AD risk and 
progression. One mechanism by which this may occur is that exaggerated 
cerebrovascular exposure to Aβ compromises BBB integrity resulting in a shift in Aβ 
transport from blood to brain. My research group previously reported that significant 
Aβ in plasma is associated with TRLs and stimulated in response to the ingestion of 
particular fats. TRL-Aβ may contribute to BBB dysfunction and cerebral Aβ 
accumulation if plasma concentration is increased. To explore this possibility further, 
cerebral immunoreactivity to apo B was investigated in amyloid transgenic mice. The 
APP/PS1 transgenic mice have an 8-fold greater concentration of TRL-Aβ in plasma 
than wild type mice.  
  
The 3-D double immunofluorescent colocalization analysis technique described 
in Chapter 2 showed immunoreactivity of apo B within the core and the periphery of 
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amyloid plaques of APP/PS1 mice, providing direct evidence that peripheral Aβ 
enriched in TRL may contribute to the cerebral amyloidosis. 
 
 
Chapter 4 – Differential effects of fatty acids on blood-brain barrier 
integrity 
 
The content of this chapter is covered by Paper 4:  
Takechi R, Galloway S, Pallebage-Gamarallage MM, Wellington CL, Johnsen RD, 
Dhaliwal SS, Mamo JC. (2009) Differential effects of dietary fatty acids on the cerebral 
distribution of plasma derived apo B lipoproteins with amyloid-β. Br J Nutr. (in press) 
 
Thesis objective addressed in this chapter: 
Objective 4: To evaluate the differential effects of dietary fatty acids on BBB integrity 
in wild-type mice and to compare this with an established murine model 
of AD (amyloid transgenic mice) 
 
 The capillary network of the brain effectively separates blood from cerebral 
spinal fluid (CSF). Tightly apposed endothelial cells bound via tight junction proteins 
characterize what is commonly referred to as the BBB and effectively exclude 
neurotoxic and inflammatory agents. In addition. plasma proteins and large 
macromolecules such as lipoproteins are prevented from entering brain parenchyma. 
However, in Chapter 3 strong immunohistochemical staining for apo B lipoproteins 
within amyloid plaque was reported in APP/PS1 mice, suggesting that plasma TRL-Aβ 
may be a source of Aβ found in the amyloid plaques of the AD brain. In the absence of 
specific transporter mechanisms, blood-to-brain delivery of plasma apo B lipoprotein-
Aβ could only occur if BBB integrity becomes compromised. 
 
The primary contention of the hypothesis presented for my candidacy is that 
chronic ingestion of SFA compromise cerebrovascular integrity resulting in delivery 
from blood to brain of TRL-Aβ. To investigate this, normal WT mice were randomized 
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to receive either a LF control diet, or chow enriched in SFA, MUFA or PUFA.  The 
integrity of the BBB was assessed by detecting the distribution in brain parenchyma of 
the plasma proteins immunoglobulin G (IgG) and of apo B containing lipoproteins. 
Colocalization of the apo B with Aβ is reported as is the abundance of the endothelial 
tight junction protein, occludin-1. In the context of amyloidosis and AD risk, 
comparisons were made with amyloid transgenic mice (APP/PS1), an established model 
of AD.   
  
 In WT mice fed an SFA enriched diet,  significant immunoreactivity of IgG was 
detected in the cerebral perivascular regions concomitant with a reduction of occludin-1 
expression and elevated plasma S100B level. The results suggest that SFA induced 
cerebrovascular dysfunction and aberrations in protein kinetics across the BBB. In 
contrast, there was no evidence of BBB disruption in mice fed a control diet, or chow 
enriched in either MUFA or PUFA. Perivascular leakage of apo B was clearly seen in 
the SFA fed mice, particularly within the cortex and the hippocampal formation and this 
was exacerbated with a longer duration of feeding. Moreover, the 3-D double 
immunofluorescent labelling technique established in Chapter 2 demonstrated the 
significant colocalization of Aβ with apo B consistent with the notion of apo B 
lipoprotein/Aβ delivery  from blood to brain.  
 
 The pattern of cerebrovascular disturbances and relative distribution of apo 
B/Aβ within particular regions of the brain paralleled that found in APP/PS1 amyloid 
transgenic mice, that had substantial elevations in plasma TRL-Aβ because of amyloid 
over-expression.  
 
 Collectively, the data presented in this manuscript is consistent with the 
hypothesis that chronic ingestion of SFA may cause disruption of BBB function which 
may result in significant blood-to-brain delivery of TRL-Aβ. The findings provide one 
possible explanation for epidemiological studies that show a positive association in AD 
risk with dietary SFA. The differential effects of fatty acids on BBB function and apo 
B/Aβ cerebral distribution were published in the British Journal of Nutrition. Parallel 
xx 
studies investigating the effects of dietary cholesterol supplementation on BBB function 
are presented in Chapter 5. 
 
Chapter 5 – Discussion and conclusion 
 
The content of this chapter is covered by Paper 5:  
Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Mamo JC. (2009) 
Dietary fats, cerebrovascular integrity and Alzheimer’s disease risk. Prog Lipid Res. (in 
press) 
 
Thesis objectives addressed in this chapter: 
Objective 5: To provide informative consideration of whether disturbances in 
cerebrovascular integrity in part explain the positive association between 
dietary SFA/cholesterol ingestion and AD risk 
 
 
 The principal findings of immunoreactive apo B within cerebral plaque (Chapter 
3) and the differential effects of fatty acids on BBB integrity (Chapter 4) attracted 
significant attention with invitations to present the findings at several conferences (see 
Appendix C). The Chief Editor of the prestigious journal Progress in Lipid Research 
invited me to submit a review (impact factor: 11.2) to present my hypothesis in greater 
detail. The review was written in an hypothesis generating context and takes into 
consideration a substantial body of literature (192 references) and additional studies 
done by me.  
 
 Key concepts discussed in the review is the suggestion that dietary SFA and 
cholesterol induce cerebrovascular disturbances that can be independent of an increased 
concentration in plasma Aβ. Synergistic effects of apo B lipoproteins with apo E is 
considered because of the significant differences in AD risk with apo E isoforms and 
because of the importance of apo E in TRL-lipoprotein metabolism. Evidence for the 
association of apo B/Aβ containing lipoproteins with specific heparin-sulphate 
xxi 
proteoglycans is presented and consideration of how this occurs is discussed. The 
review supports the contention that AD is characterized by significant cerebrovascular 
disturbances preceding frank amyloidosis and that the latter is more likely to exacerbate 
inflammatory pathways.  
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An emerging body of evidence is consistent with the hypothesis that dietary fats influence Alzheimer’s
disease (AD) risk, but less clear is the mechanisms by which this occurs. Alzheimer’s is an inflammatory
disorder, many consider in response to fibrillar formation and extracellular deposition of amyloid-beta
(Ab). Alternatively, amyloidosis could notionally be a secondary phenomenon to inflammation, because
some studies suggest that cerebrovascular disturbances precede amyloid plaque formation. Hence, die-
tary fats may influence AD risk by either modulating Ab metabolism, or via Ab independent pathways.
This review explores these two possibilities taking into consideration; (i) the substantial affinity of Ab
for lipids and its ordinary metabolism as an apolipoprotein; (ii) evidence that Ab has potent vasoactive
properties and (iii) studies which show that dietary fats modulate Ab biogenesis and secretion. We dis-
cuss accumulating evidence that dietary fats significantly influence cerebrovascular integrity and as a
consequence altered Ab kinetics across the blood–brain barrier (BBB). Specifically, chronic ingestion of
saturated fats or cholesterol appears to results in BBB dysfunction and exaggerated delivery from
blood-to-brain of peripheral Ab associated with lipoproteins of intestinal and hepatic origin. Interest-
ingly, the pattern of saturated fat/cholesterol induced cerebrovascular disturbances in otherwise normal
wild-type animal strains is analogous to established models of AD genetically modified to overproduce
Ab, consistent with a causal association. Saturated fats and cholesterol may exacerbate Ab induced cere-
brovascular disturbances by enhancing exposure of vessels of circulating Ab. However, presently there is
no evidence to support this contention. Rather, SFA and cholesterol appear to more broadly compromise
BBB integrity with the consequence of plasma protein leakage into brain, including lipoprotein associated
Ab. The latter findings are consistent with the concept that AD is a dietary-fat induced phenotype of vas-
cular dementia, reflecting the extraordinary entrapment of peripherally derived lipoproteins endoge-
nously enriched in Ab. Rather than being the initiating trigger for inflammation in AD, accumulation of
extracellular lipoprotein-Ab may be a secondary amplifier of dietary induced inflammation, or possibly,
simply be consequential. Clearly, delineating the mechanisms by which dietary fats increase AD risk may
be informative in developing new strategies for prevention and treatment of AD.
 2009 Elsevier Ltd. All rights reserved.
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1. Introduction
Hallmark pathological characteristics of advanced Alzheimer’s
disease (AD) include hyperphosphorylation of the microtubular
protein tau in neurons and extracellular deposits of protein that
are enriched in the protein amyloid-beta (Ab) [1,2]. The formation
of tau-tangles results in neuronal synapse dysfunction and eventu-
ally loss of cell-cell communication, whereas disturbed Ab kinetics
may be pivotal to pro-inflammatory pathways that compromise
cellular integrity [1,3,4]. Despite a substantive body of research,
it is presently difficult to equivocally delineate if these pathological
features of AD are causal or consequential [5,6], emphasising the
therapeutic challenge of identifying the inflammatory triggers that
compromise cellular integrity.
Earlier research primarily focussed on the neuronal biogenesis
of Ab in the context that overproduction may initiate formation of
fibrillar Ab deposits and thereafter inflammation [7–10]. All muta-
tions known to cause AD increases the production of Ab peptide.
However, in sporadic and late onset AD, the most common form
of AD, Ab biosynthesis is comparable to otherwise healthy
individuals [11]. Alternatively, insufficient removal of Ab from
cerebrospinal fluid (CSF) has also been proposed as a mechanism
for Ab oligomerization [12–14]. However, the brain seems
potently equipped with substantive efflux processes that would
otherwise prevent this. It is estimated that CSF is replenished
some three times daily via the choroid plexus and indeed the
epithelial cells of the choroid plexus host an array of enzymes
which effectively hydrolyse potentially toxic proteins including
Ab [15]. In addition, the endothelial cells of the cerebrovascula-
ture host receptor-proteins that permit reciprocal transfer of Ab
across the blood–brain barrier (BBB) [16–20]. Collectively,
there seems to be exquisite cerebral Ab homeostatic
mechanisms and therefore the concept that cerebral Ab-over-
load triggers inflammatory pathways seems physiologically
unlikely.
Alzheimer’s disease is a chronic disorder and shares risk factors
with other diseases such as non-insulin dependent diabetes and
cardiovascular disease (CVD) [21–25]. However, chronic diseases
are often ‘spectrum disorders’ with multiple aetiology. For exam-
ple, obesity is a major risk factor for diabetes and CVD [26,27],
but not a requisite feature per se and 40% of subjects who experi-
ence a coronary event are normolipaemic [26,27]. Indeed, choles-
terol infiltration is not always found in atherosclerotic plaque
and there is substantial heterogeneity in the extent of smooth
muscle cell proliferation and tissue calcification [28,29]. Such par-
adoxes raise the possibility that amyloidosis is simply one of many
‘triggers’ for dementia per se.
Common to chronic disorders, there is ample evidence that life-
style influences AD risk and progression. Good nutrition, physical
activity and environmental enrichment confer synergistic reduc-
tion in AD risk [30–37]. However, in a therapeutic context, less is
known of the efficacy of lifestyle interventions on disease progres-
sion, perhaps confounded by the diversity of dementia phenotypes.
Given that within 20 years the expected global health burden for
dementia, of which AD accounts for 80%, will exceed treatment
of any other chronic disease [38–40], exploring lifestyle therapies
has become as much an economic imperative as a therapeutic
priority.
Most AD research has focused on damage of neurons, however
there is an increasing effort to understand the possibility of cere-
brovascular dysfunction as a primary risk factor for AD. This para-
digm shift is arguably warranted because vascular alterations
including endothelial and smooth muscle cell proliferation precede
frank amyloidosis [41]. Blood plasma proteins have been detected
in the parenchyma of AD brains [42,43] and inflammatory sequelae
are commonly reported [44,45], observations that are consistent
with breakdown of the BBB. Targeting vascular disturbances rather
than Ab deposition may therefore be an appropriate first-focus
strategy for prevention and treatment of AD.
It is reasonable to suggest that diet is important in maintaining
cerebrovascular integrity [46] particularly given the overwhelming
evidence that it contributes substantially to coronary artery health
and CVD risk [47–53]. Population studies also generally support
this contention. Saturated fats and cholesterol are both positively
associated with AD risk [54–60] and in animal models, including
amyloid transgenic mice, saturated fat (SFA) and cholesterol in-
duce or exacerbate cerebral amyloidoisis [61–64]. The studies in
transgenic amyloid mice are certainly consistent with a vascular
contribution to disease over and above exaggerated Ab biogenesis.
The purpose of this review is to provide contemporary consid-
eration of the mechanisms by which dietary fats influence AD risk.
Specifically, this article will focus on the putative interrelationship
between plasma lipoproteins, peripheral Ab kinetics and cerebro-
vasculature integrity.
2. Dietary fats and Alzheimer’s disease risk
2.1. Population, clinical and animal model studies
Population studies support a role of dietary fats in AD, although
this remains controversial. Laitinen reported that intake of unsatu-
rated fats is protective, whereas intake of saturates increases risk
of AD [60]. In the Framingham study, the top quartile of plasma
docosahexanoic acid (DHA) (profoundly influenced by diet) was
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associated with a 47% reduction in risk of all-cause dementia [65].
Strong evidence continues to come from animal studies. Many
studies show that cerebral amyloid burden and Alzheimer-like
pathology is attenuated by a diet enriched in DHA in amyloid dou-
ble transgenic [62,66–69]. Not surprisingly such findings have
stimulated research to explore the benefits of diets low in SFA
and cholesterol, such as the Mediterranean diet [47,51,70,71].
The omega 3 and 6 poly-unsaturated fatty acids (n3/n6 PUFA) have
attracted particular interest. DHA and eicosapentaenoic acid (EPA)
make up some 40–50% of cerebral fatty acids and are critical to
neuronal plasticity and in addition may be therapeutically benefi-
cial because of anti-inflammatory properties [69,72]. An increasing
number of clinical studies demonstrate better cognitive perfor-
mance in subjects with AD receiving n3 fatty acid supplementation
[73] and meta-analysis is consistent with such a purported benefit
[56,70]. However, the evidence that n3/6 intake reduces prevalence
of AD is presently less convincing [74]. The mechanisms by which
n3/6 confer protection have been elegantly summarized and will
not be detailed here, suffice to say that these include the preven-
tion of neuronal cell death, regulation of gene expression and
anti-oxidative and anti-inflammatory functions [75–80].
2.2. Saturated fatty acids, amyloid-beta and the small intestine
The mechanisms by which dietary fats such as SFA increase AD
risk may seem less of a scientific priority to delineate compared to
dietary compounds that confer protection. Yet in some chronic dis-
orders this approach has proven pivotal to developing effective
therapeutic strategies for prevention and treatment of disease.
For example, elucidating the role of cholesterol in atherosclerosis
and cardiovascular disease led to the evolution of relatively safe
and effective cholesterol-lowering drugs. Hence, significant atten-
tion will be provided in this article of possible pathways by which
dietary fats increase AD risk and as a hypothesis-generating
exercise.
Amyloid-beta is an amphiphylic protein normally chaperoned
by transporter proteins [81]. However, strong hydrophobic do-
mains have made distributional analysis of Ab in blood and tissues
difficult, because lipids often mask the immunodetection method-
ologies used to measure concentration [82,83]. Exogenous addition
to blood of pre-solubilised Ab suggests that less than 5% of Ab
binds to lipoproteins [84]. However, plasma lipoprotein fraction-
ation and delipidation reveal that significant quantities of endoge-
nous Ab are associated with lipoproteins, particularly those
enriched in triacylglycerol (TAG) [85]. The latter is also supported
by studies in cell culture, which demonstrated that hepatocytes se-
crete Ab as a lipoprotein complex [86].
Absorptive epithelial cells of the small intestine were more re-
cently identified as another potential significant source of plasma
Ab [87–90] (Fig. 1). Enterocytic Ab is enriched in the perinuclear re-
gion and within the lacteals, the site of chylomicron assembly and
secretion respectively [90,91] and Ab colocalizes with apolipopro-
tein (apo) B, an obligatory component of nascent chylomicrons
(Fig. 1). Oral fat challenges in healthy subjects demonstrate a
post-prandial Ab response [92] and plasma kinetics of chylomi-
cron-Ab exactly parallels the metabolic pathway of the lipoprotein
particle [93]. Indeed, given that Ab significantly inhibits hepatic
uptake of chylomicrons, one of its physiological roles is probably
as a regulating apolipoprotein of TAG-rich lipoproteins (TRLs).
Dietary-fat regulation of enterocytic Abproduction and secretion
was demonstrated in wild-type mice fed a SFA-enriched diet. Com-
pared to low-fat fed controls, SFA substantially increased enterocy-
tic Ab, whereas fasting completely abolished Ab immunoreactivity
[87]. On the basis that SFA also suppress expression of receptors that
are responsible for clearance of apo B lipoproteins [94–96], the find-
ings raise the intriguing notion that dietary SFA may induce a state
of post-prandial-hyperamyloidemia. Aberrations in chylomicron
kinetics have been commonly reported in subjects with or at risk
of CVD including otherwise normolipaemic subjects [97,98]. Chylo-
micron remnants are found in atherosclerotic plaque and may con-
tribute significaintly to cholesterol deposition and inflammatory
pathways [28,99,100]. Several lines of evidence are consistent with
the notion that chylomicron-hyperamyloidemia may also contrib-
ute directly to amyloidosis and AD risk. Firstly, in clinical studies,
Fig. 1. Small intestine enterocytic abundance of amyloid-b and apolipoprotein B in saturated fat or cholesterol supplemented mice. The enterocytic perinuclear production
and secretion into the lacteal of amyoid-b (Ab) (top row) and apo B (bottom row) are shown in mice fed either a low-fat control, saturated fat enriched (SFA) or cholesterol
supplemented (Chol) diet for 6 months. There was a significant increase of Ab abundance concomitant with apo B in SFA-fed mice compared to control group. The cholesterol
supplemented diet increased apo B abundance but had no significant effect on Ab. Scale bar indicates 50 lm. Magnified images are also shown in each insert with 5 lm scale
bar.
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subjects with AD or mild cognitive impairment (MCI) have signifi-
cantly greater plasma Ab in a plasma TRL fraction that includes chy-
lomicrons [85]. Moreover, plasma apo B48 (an exclusive marker of
chylomicrons) was increased fourfold in post-absorptive AD sub-
jects compared to age matched controls [85]. In amyloid transgenic
mice that are established models of AD, onset and progression of
disease was found to strongly correlate with secretion into blood
of TRL-Ab and plasma TRL-Ab concentration [101]. In addition, stud-
ies showed apo B immunoreactivity associatedwith amyloid plaque
of human brain specimens [102]. However the latter was not con-
sidered in the context that it may have reflected blood-to-brain
delivery of plasma lipoprotein derived Ab.
3. Blood-to-brain delivery of triacylglycerol-rich-lipoprotein
amyloid-beta
3.1. Receptor mediated cerbrovascular amyloid-beta kinetics
The receptor for advanced glycosylation end products (RAGE) is
one endothelial cell protein found to facilitate Ab transfer from
blood-to-brain [16,17]. However, there is no evidence that TRL or
lipoproteins per se bind to RAGE, requiring therefore transfer of
Ab from the lipoprotein particle to the aqueous mileu prior to
transport via this pathway. However, in vivo and in vitro studies
suggest that Ab binds tightly to TRL and is not shed or transferred
to other chaperone transporters [93], so RAGE-mediated transfer of
lipoprotein derived Ab seems unlikely.
The low-density-lipoprotein receptor related protein-1 (LRP1) is
expressed within the cerebrovascular endothelial cell junctions
and binds with substantial affinity to both ‘free’ Ab as well as to
TRL-remnant lipoproteins that have become depleted of TAG.
However, LRP1 is considered to be principally involved in cerebral
efflux of Ab to blood rather than influx of Ab from plasma
[12,13,17]. In AD subjects and animal models there appears to be
a shift in RAGE relative to LRP expression [13,17,103,104], consis-
tent with the possibility of a gradient shift of Ab kinetics from
blood-to-brain, but it is presently unclear if this pathway is rele-
vant to TRL-Ab metabolism.
3.2. Vasoactive active properties of amyloid-beta
Cerebral extravasation of TRL-Ab may also occur non-specifi-
cally because of broader disruption of the cerebrovasculature. Plas-
ma proteins, including apo B, have been reported in CSF and
parenchyma of subjects with AD [42,44,102,105]. Indeed, raised
TRL-Abmay be responsible of the vascular disturbances which lead
to increased rates of peripheral delivery [101,105,106]. Indirect
evidence that TRL-Ab may have vasoactive properties is provided
by cell culture and animal model studies which investigated the ef-
fect of exogenous Ab administration. Intravascular administration
of solubilised Ab induces significant endothelial cell damage with
changes in the cell membrane, cytoplasm, nucleus and other
organelles [107]. Sequestration of Ab within brain capillaries was
reported in several studies [18–20] and longer term administration
of Ab (2 weeks), resulted in a significantly compromised BBB and
activated central-nervous-system glial cells [108].
The exposure of blood vessels to exogenous Ab induces en-
hanced vasoconstriction and diminished vasodilation accompanied
with lack of elasticity that are commonly seen in aged animals. In a
study by Thomas et al. loss of endothelial function was demon-
strated with acute Ab exposure of bovine cerebral middle artery
[107]. This vascular damage was prevented by the anti-oxidant en-
zyme superoxide-dismutase and the free radical scavenger PBN12,
suggesting that reactive oxygen species may be involved in the
vasoconstrictive action of Ab. Morphological disturbances includ-
ing necrotic cell damage accompanied the inflammatory response
induced by Ab exposure.
Animal model studies confirm blood-to-brain delivery of Ab
when the plasma concentration is chronically elevated. In study
by LaRue et al., transport of Ab across the BBB was increased eight
fold in amyloid transgenic mice compared to wild-type controls
[109], a process that could be inhibited by immunization [12].
3.3. Dietary saturated fats and blood–brain delivery of lipoprotein
associated amyloid-beta
The vasoactive properties of exogenous Ab and in hyperamyloi-
dic transgenic mice led us to explore the hypothesis that dietary
SFA increases plasma TRL-Ab and that with chronic ingestion this
consequently leads to blood-to-brain delivery of TRL-Ab. In a re-
cent study, wild-type mice were fed diets modified diets enriched
in either SFA, monounsaturated (MUFA) or poly-unsaturated
(PUFA) fatty acids and compared with low-fat fed controls [106]
(Fig. 2). Following 3 months of dietary intervention there was
remarkable parenchymal colocalization of Ab with apo B immuno-
reactivity in SFA-supplemented mice. Six months of SFA feeding in-
creased immunoreactive Ab/apo B compared to the 3 month fed
group and the pattern of distribution was remarkably similar to
Ab/apo B colocalization in APP/PS1 amyloid transgenic mice with
cortex > brain stem > hippocampal formation. However, there
was no evidence that TRL-Ab delivery to brain occurred in either
MUFA, PUFA or low-fat fed mice.
A shift in receptor-mediated transport across the BBB may have
contributed to extravasation of apo B-Ab in SFA mice. However,
several other markers suggest that was more likely to be a non-
specific phenomenon. Immunoglobulin G (IgG), a large molecular
weight plasma protein, was evident in parenchyma of SFA-fed mice
and occludin expression, the primary endothelial tight junction
protein was substantially reduced compared to controls. In addi-
tion, the plasma concentration of S100B, a CSF abundant protein,
was increased in plasma suggesting bidirectional disturbances in
protein transport across the BBB.
4. Saturated fatty acid induced disturbances in blood–brain
barrier integrity
4.1. Triacylglycerol-rich-lipoprotein amyloid-beta-induced
cerbrovascular disturbances
It is proposed that post-prandial hyperamyloidemia is one pos-
sible mechanism for SFA-induced BBB dysfunction and delivery of
TRL-Ab from blood-to-brain, but presently this remains to be
substantiated. Rather, we found that the plasma concentration of
Ab1–40 and Ab1–42 in SFA-fed mice was similar to mice maintained
on either MUFA, PUFA or low-fat (control) diets [106] (Fig. 2).
However, caution must be exercised with this interpretation.
Post-prandial hyperamyloidemia may not have been apparent in
those studies because the mice had been deprived of food for
approximately 6 h before blood was sampled. Alternatively, repet-
itive but transient (post-meal) exposure to post-prandial-Ab may
be sufficiently damaging to endothelial integrity, without inducing
a state of basal hyperamyloidemia. Consistent with this concept, in
non-demented participants significant variation in CSF-Ab levels of
1.5- to 4-fold were detected over 36 h of serial sampling. Amyloid-
b1–40 and Ab1–42 were highly correlated over time indicating that
similar processes regulate the concentration of these isoforms.
On average, the fluctuations of Ab levels appeared to be time of
day or activity dependent [110]. Methodological limitations may
also be a confounder in interpretation. It is possible that the immu-
noassays used to measure plasma Ab are not sensitive to the lipi-
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dated form of Ab and are unable to detect the putative SFA-induced
increase in this pool of Ab.
4.2. Saturated fatty acid induced amyloid-beta independent
cerebrovacular disturbances
Several non-Ab mediated pathways could also contribute to
SFA-induced cerebrovascular disturbances. Dietary ‘lipotoxicity’
refers to the processes leading to end-organ damage and/or dys-
function following excess exposure to fatty acids identified in the
context of fat-induced insulin resistance [111]. However, the pro-
cess has also been implicated in endothelial dysfunction and ath-
erosclerosis, heart failure, kidney failure, steatohepatitis and liver
failure, autoimmune inflammatory disorders, susceptibility to
infections, cancer and ageing. Significant differences in the cyto-
toxic effects of fatty acids have been reported, with longer chain
SFA’s being the most potent and the mono- and poly-unsaturated
fatty acids being cytoprotective [112]. Morgan [112] suggests that
the underlying toxicity of SFA is a consequence of disturbances in
protein processing and endoplasmic reticulum dysfunction, for
example apoptotic induction. One relevant example was a study
by Patil et al. who found that palmitic acid induced region-specific
cerebral damage because of higher fatty acid-metabolizing capac-
ity of cortical astroglia [113]. Conversely, cell culture studies sug-
gest that incubation, particularly with longer chain unsaturates
has an antagonistic effect on endoplasmic reticulum-centred stress
pathways [114]. If this were the case, then amyloidosis may be a
phenomenon secondary to cerebrovascular inflammation.
Animal feeding studies have shown that typical Western diets
substantially increase protein oxidation and lipid peroxidation
[115,116]. In APP/PS1 mice, this occurred in the absence of in-
creased Ab levels [115]. In addition, differences in membrane lipid
status as a consequence of diet may influence the propensity for Ab
oligomerization to occur [117]. Exogenous fatty acid supplementa-
tion results in significant shifts in neuronal phospholipids and in
lipid raft composition [118–120], key regulators of cell protein
transport and inflammation. Dietary fats also influence expression
of critical genes involved in Ab kinetics, for example the scavenger
protein transthyretrin [77]. An alternate perspective is provided by
Hooijmans and colleagues, who suggested that dietary fats influ-
ence AD risk because of chronic changes in cerebral hemodynamics
[68]. In APP/PS1 mice fed DHA, plaque burden was attenuated
probably because of greater blood circulation in the brain due to
vasodilation. In contrast a Western diet rich in saturated fats and
cholesterol increased amyloidoisis but without any changes to
net blood volume or flow.
4.3. Cholesterol-induced disturbances in blood–brain barrier integrity
Studies by Ghbiri et al. found that like SFA, dietary cholesterol
results in BBB dysfunction in New Zealand white rabbits [121].
Chronic dietary cholesterol supplementation also results in cere-
bral amyloidosis in wild-type rabbits, but this was not explored
in the context of raised plasma TRL-Ab [61]. However, indirect evi-
dence that aberrant lipoprotein metabolism is involved in NZ-
White rabbits fed cholesterol is suggested by the observation that
the animals become grossly hypercholesterolemic as a conse-
quence of apo B lipoprotein accumulation.
We have confirmed that modest dietary supplementation with
cholesterol disturbs BBB function and, like SFA, extravasation of
apo B/Ab is observed within the brain parenchyma [106]. However,
unlike the rabbit studies, mice were normolipaemic. Dietary cho-
lesterol supplementation also had no measurable effect on plasma
Ab1–40 or Ab1–42 in wild-type mice (albeit with the caveats in mea-
surement discussed), consistent with the concept that the effects
on BBB function were plasma Ab independent. Cell culture studies
suggest several mechanisms by which dietary cholesterol may be
toxic. Frears et al. observed that, in the presence of cholesterol, hu-
man AbPP transfected HEK cells secrete greater quantities of Ab
[122]. However, the effects of cholesterol on Ab biosynthesis are
uncertain because cholesterol lowered Ab synthesis in primary cell
cultures of rat embryo hippocampal neurones [123] and dietary
cholesterol reduces enterocytic abundance of Ab [89]. Clearly, the
effects of dietary cholesterol on net TRL-Ab secretion in vivo need
to be established. Alternatively, Subasinghe et al. showed that cho-
lesterol can enhance Ab induced toxicity because of increased pro-
tein binding to the plasma membrane and accelerated
oligomerization of Ab [124]. Yao and colleagues suggest that like
SFA, excess cholesterol causes ER and mitochondrial stress that
can lead to apoptosis [125,126]. Mitochondrial activity or lyso-
somal processing can result in the production of oxidized lipids
including cholesterol. A number of studies support the contention
that oxidized lipids compromise tissue integrity and exacerbate
inflammatory pathways [127,128]. Interestingly, Stanyer and col-
leagues reported that plasma lipoproteins, particularly when oxi-
dized, promote Ab polymerization [129].
Fig. 2. Integrity of blood–brain barrier shown by the cerebral distribution of plasma immunoglobulin G. The cerebral distribution of immunoglobulin G (IgG) is shown in mice
fed either a low-fat control, saturated fat enriched (SFA) or cholesterol (Chol) supplemented diet for 60 days. Significant peri-vascular leakage of IgG was seen in both SFA and
cholesterol fed mice consistent with BBB dysfunction. Fourteen days after replacing the SFA diet with the low-fat diet (SFA? LF) IgG extravasation persisted. Scale bar in top
and bottom row represents 100 lm and 30 lm, respectively.
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5. Apolipoprotein E phenotype, apo B-amyloid beta metabolism
and Alzheimer’s disease risk
5.1. Apolipoprotein E isoforms and Alzheimer’s disease risk
Inheriting one or two alleles for apo E4 increase the risk of AD
by 17% and 43%, respectively, compared to individuals hetero- or
homo-zygous for apo E2 and E3 isoforms [130]. A number of
hypotheses have been put forward for the positive association of
AD with apo E4 and reviewed extensively in the literature
[92,131–139]. Briefly, key concepts include; poorer sequestration
of soluble Ab and hence a propensity for oligomers to form; in-
creased Ab biosynthesis by regulating the activities of APP cleavage
enzymes of beta- and gamma-secretase; disturbances in choles-
terol homeostasis, which in turn will regulate Ab biogenesis; pro-
inflammatory and oxidative stress triggers; improper maintenance
of BBB integrity; and defective neuronal growth. In this review, we
wish to also consider the possibility that apo E isoforms influence
AD risk via differential modulation of TRL metabolism.
5.2. Apolipoprotein E isoforms and triacylglycerol-rich-lipoprotein
metabolism
More than 98% of plasma apo E exists in a lipidated form, prin-
cipally bound to post-hydrolyzed TRL-remnants [140,141]. Apo E is
the principal protein of chylomicrons, making up approximately
65% of total protein mass [142]. The acquisition by TRL of apo E
inhibits interaction with endothelial lipases, serving instead as
the binding ligand to high affinity receptors involved in TRL-rem-
nant uptake [143–145]. The primary receptor responsible for
TRL-remnant uptake is the low-density-lipoprotein receptor
(LDL-r), however if this pathway becomes rate-limiting other high
affinity processes such as lipoprotein–receptor-related protein one
LRP1 may partially compensate.
In man, the three principal apo E isoforms are differentially
distributed, probably because of differences in lipophilicity. Curi-
ously, apo E4 is distributed with remnant lipoproteins that
contain relatively more TAG (principally chylomicrons), whereas
apo E2 and apo E3 tend to be primarily associate with hepatically
derived TRL remnants, (i.e. intermediate density lipoproteins)
[146].
There are several pathways by which apo E or specific variants
may synergistically influence TRL-Abmediated AD risk. Firstly, apo
E4 does not support proper BBB functionality compared to apo E2
and E3 [103] which may result in amplified blood-to-brain delivery
of plasma proteins including TRL-Ab. Apo E per se has significant
affinity for extracellular matrices in particular the heparin sulphate
proteoglycans (HSPG). Physiologically this is an important function
as it facilitates interaction with proteins involved in receptor-med-
iated uptake. Binding of apo E to HSPG is an initial step in the local-
ization of TRL-remnant to the surface of several different types of
cells. Thereafter, the TRL-remnants are transported into the cell
by receptor-mediated pathways, or by direct uptake of apoE-con-
taining lipoprotein-HSPG complex [135]. Studies by Libeu et al.
found that apo E has an HSPG-binding site highly complementary
to heparin sulphate rich in N- and O-sulfo groups in the brain and
liver [147].
The physiological effect of apo E variant on HSPG binding is dif-
ficult to predict although mutations in apo E have demonstrated
potentially substantial differences in affinity [148,149], Arg-142
[150,151], Arg-145 [151], and Lys-146 [152]. However, the dissoci-
ation constant of equilibrium KD of the principal apoE isoforms and
glycosaminoglycans (GAGs) was found to be similar [153]. Collec-
tively, apo E maymediate extracellular retention of TRL-Ab if deliv-
ered from blood-to-brain but presently there is no clear evidence
to suggest this would be exacerbated in individuals who express
the apo E4 variant.
In atherosclerotic plaque, retention of apo B/E lipoproteins
within the subendothelial space is considered the triggering event
for monocyte infiltration. Activated macrophages are potently
equipped with an array of receptors capable of internalizing TRL-
Ab [154]. Apo E serves as the principal lipoprotein binding ligand
for many of these uptake pathways including the LDL-r and
LRP1. Activated macrophages will secrete substantial quantities
of apo E to enhance the efficiency of lipoprotein internalization
[155]. Oxidative modification of lipoproteins may occur particu-
larly if retention is prolonged. Modification, enables macrophage
internalization by additional apo E mediated pathways, such as
via the scavenger receptor [156] and the oxidized LDL receptor
LOX-1 [157]. Evidence that apo E variants may influence the
inflammatory pathway comes from primary cultures of macro-
phages. Macrophages expressing apo E4 enhanced atherosclerotic
pathways compared to apo E3 macrophages, by promoting LDL-r
mediated lipoprotein uptake [158]. Moreover, apo E4 was also
found to be less efficient at conferring oxidative protection than
apo E3. In another study the murine monocyte–macrophage cell
line (RAW 264.7) was stably transfected to produce equal amounts
of human apoE3 or apoE4. Following lipopolysaccharide stimula-
tion, apoE4-macrophages showed higher and lower concentrations
of tumour necrosis factor alpha (pro-inflammatory) and interleu-
kin 10 (anti-inflammatory). In addition, increased expression of
heme oxygenase-1 (a stress-induced anti-inflammatory protein)
was observed in the apoE4-cells. The apoE4-macrophages also
had an enhanced transactivation of the key redox sensitive tran-
scription factor NF-jB.
A number of studies have shown that TRL-remnants are effi-
ciently degraded by macrophages. If uptake occurs, a mitochon-
drial respiratory burst and lysosomal exocytosis results in the
release of potent cytotoxic compounds such as superoxide, which
compromise cellular integrity [159]. Proteinaceous deposits may
be formed if cell death occurs and it is likely this exacerbates
inflammatory pathways. The latter would suggest that amyloidosis
is a secondary inflammatory trigger but pivotal to a subsequent
cyclic phenomenon. Glial cell activation is the hallmark of inflam-
mation in the brain [160]. Activated microglia produce inflamma-
tory molecules such as cytokines, growth factors and
complement proteins [161–163]. These mediators of inflammation
in turn activate other cells to produce additional signalling mole-
cules that further activate microglia in a positive feedback loop
to perpetuate and amplify the inflammatory signalling cascade
[164].
Apo E is an important ligand for binding of TRL-remnants to
LRP1, a key endothelial junction protein thought to primarily facil-
itate cerebral efflux of Ab. However, in cultured 293 cells, LRP1 had
approximately equal affinity for apo E2/E3 and E4 [165], suggest-
ing that cerebrovascular-mediated efflux of Ab via LRP would not
be unduly different in subjects with apo E4 alleles.
6. Apolipoprotein B/amyloid beta association with
proteoglycans in a murine model of Alzheimer’s disease
6.1. Apolipoprotein B association with agrin, perlecan, biglycan and
decorin
Proteoglycans are major components of the extracellular matri-
ces, comprised of one or more glycosaminoglycans chains cova-
lently attached to a core protein [166]. Proteoglycans may serve
as binding sites for receptors, or as mediators of cell adhesion,
migration and proliferation [166]. Studies over the past decade
suggest that proteoglycans, in particularly heparin sulfate proteo-
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glycans, contribute towards the formation and thereafter stability
of amyloid plaques [167]. However, their putative role in lipopro-
tein-Ab entrapment has not been considered.
Proteoglycans bind apo E and apo B via ionic interactions with
the core protein of proteoglycans [168,169] and proteoglycan med-
iated retention of apo B/E lipoproteins within the subendothelial
space of arterial vessels is considered as the initiating event for
atherosclerosis [170,171].
We suggest four proteoglycans that may be of particular impor-
tance to parenchymal binding of TRL-Ab. Agrin is an extracellular
matrix-associated HSPG pivotal for the development and the main-
tenance of the BBB and the formation of the neuromuscular junc-
tion [172]. Agrin exhibits structural similarity to perlecan, a
proteoglycan reported to bind apo B lipoproteins in the hepatic
sinusoidal space [173].
Perlecan, the largest extracellular matrix HSPG, has the capacity
to facilitate the interaction of apo B and E lipoproteins with recep-
tor-mediated pathways [173,174]. Perlecan exhibits structural
homology to the ligand binding region of LDL-r, the primary path-
way for apo B and apo E rich particle internalization [173,175].
Perlecan over-expression within the subendothelial space of coro-
nary vessels has been implicated in the pathogenesis of atheroscle-
rosis as a consequence of increased lipoprotein retention [176].
Cerebral biglycan expression in AD has not been reported. How-
ever, biglycan has significant affinity for apo B and E containing
lipoproteins [177,178] and may contribute to the cerebral reten-
tion of TRL-Ab. In atherosclerotic tissue, biglycan abundance is sub-
stantially greater in comparison to healthy tissue [179,180].
Moreover, there is a positive association between biglycan and
arterial accumulation of apo B and E containing lipoproteins
[177,178]. Decorin exhibits structural homology to biglycan
(57%), including the apo B/E binding domain [173].
An immunhistological approach was used to investigate the
putative colocalization of apo B/Ab with agrin, perlecan, biglycan
and decorin in an established murine model of AD. Double trans-
genic amyloid mice (APP/PS1) have an eightfold higher concentra-
tion of Ab compared to wild-type mice and develop cerebral
amyloid plaque by 6 months of age [105]. In APP/PS1 mice, focal
accumulation of apo B lipoproteins was found with Ab-plaque
(Fig. 3). We found enrichment in cerebral amyloid deposits of the
proteoglycans, agrin, perlecan, biglycan and decorin within the
core of dense Ab-plaque and an example of the perlecan/apo B/
Ab collocation is shown in Fig. 3. The Pearson’s correlation coeffi-
cient was used as a measure of interdependent proteoglycan/apo
B/Ab association [181]. Of the four proteoglycans investigated,
perlecan, biglycan and decorin were all positively associated with
apo B lipoprotein abundance and with Ab (Lam, Takechi and
Mamo, unpublished data). These findings suggest that some prote-
oglycans contribute to Ab retention and by extension amyloidosis,
whilst other proteoglycans may have different functions, for exam-
ple plaque stabilization [174,182,183].
7. Do hepatic and intestinally-derived apo B lipoproteins both
contribute to Alzheimer’s disease risk via increased blood-to-
brain delivery and extracellular entrapment?
7.1. Apolipoprotein B isoforms and triacylglycerol-rich-lipoprotein
kinetics
In man, hepatically derived TRL can be distinguished from chy-
lomicrons based on the apo B100 and apo B48 isoforms respectively
[184,185]. Apo B48 is synthesized in enterocytes as a consequence
of mRNA processing and essentially represents half of the apo B100
amino acid sequence. It’s not clear why this editing process occurs
specifically in absorptive epithelial cells of the small intestine of
man, suffice to say that this may be responsible for constitutive
rates of chylomicron biogenesis in the absence of ingested fats.
Nascent TRL secreted from liver and intestine share similar met-
abolic pathways but there are some significant differences in
metabolism which may be important in understanding AD risk.
Chylomicrons and very low density lipoprotein (VLDL) interact
Fig. 3. The colocalization of apolipoprotein B, perlecan with cerebral amyloid plaques in amyloid transgenic mice. A 3-D triple immunofluorolabelling technique was utilized
to investigate the colocalization of apolipoprotein B (apo B) and the proteoglycans perlecan, biglycan, agrin and decorin in the amyloid plaques of APP/PS1 transgenic amyloid
mice. A representative image of apo B and perlecan colocalization is shown. There was significant colocalization of all four proteoglycans with amyloid plaque, but only
perlecan, biglycan and decorin were positively associated with apo B lipoprotein retention (Lam, Takechi and Mamo unpublished observations). One unit of scale is indicative
of 5 lm.
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with endothelial lipases and become progressively depleted in
TAG. The apo E rich post-hydrolyzed remnants then bind to recep-
tors responsible for internalization. Chylomicrons are generally lar-
ger than VLDL and contain more TAG, yet hydrolysis to the
remnant form is quicker. Once in circulation, chylomicron lipolysis
and clearance is generally complete within about 15 min. Hydroly-
sis of VLDL TAG may take up several hours and approximately half
of the VLDL-remnants will persist in circulation to become choles-
terol rich (and apo E poor) LDL.
Several, but not all clinical studies suggest that fasting plasma
apo B, which is primarily indicative of hepatically-derived lipopro-
teins, may be increased in subjects with AD [186]. Thus far only
one study reported apo B48 in AD/MCI subjects and this was found
to be substantially increased in the post-absorptive state [85].
Whilst the latter is consistent with post-prandial chylomicrone-
mia, classical oral fat challenge tests have not yet been reported
in AD/MCI subjects.
Unlike man, the liver of mice primarily secretes apo B48 and so
there is no clearly distinguishing difference per se between lipo-
proteins of intestinal or hepatic origin in this species. Preliminary
studies suggest that SFA supplementation in wild-type mice does
not have the same stimulatory effect on Ab and apo B abundance
in hepatocytes as that observed for enterocytes (Galloway and
Mamo, unpublished observations). This finding suggests that
whilst the BBB disturbances reported in wild-type mice because
of SFA feeding was specifically a post-prandial phenomenon, it
does not rule out a role for hepatically-derived lipoproteins per
se. Presently, there is no rationale to suggest that elevated apoB100
lipoprotein-Ab would be any less challenging to cerebrovascular
integrity than apo B48 lipoprotein-Ab. A fundamental question then
is whether extracellular entrapment by proteoglycans of apo B100
lipoproteins substantially differs from apo B48 lipoproteins. Both
isoforms of apo B bind to heparin proteoglycans with significant
affinity however the amino acid residues responsible differ sub-
stantially for the two isoforms [168,171]. Subtle differences in lipid
composition can profoundly affect lipoprotein interaction with
receptors and extracellular matrices so it is impossible to unequiv-
ocally say if there is a generic difference between apo B lipopro-
teins of hepatic and intestinal origin. In human atherosclerotic
plaque both apo B100 and apo B48 are found [28,175], however
there seems to be substantially more apo B48 than apo B100 relative
to the plasma concentration of the two lipoprotein subtypes [187].
In LDL-r deficient rabbits that have massively elevated levels of apo
B100 and apo B48 lipoprotein, only the latter was significantly in-
creased in atherosclerotic plaque compared to healthy arterial tis-
sue [188]. On the other hand, over-expression of human apo B
(excluding brain) induces severe neurodegeneration in transgenic
mice concomitant with elevated plasma TAG and Ab deposition
[189]. Collectively, there is some evidence to suggest that intesti-
nally-derived apo B lipoproteins may be more prone to extracellu-
lar retention. However, their concentration in blood is typically
much less than that of hepatically derived apo B lipoproteins.
Therefore, information about the relative distribution of apo B iso-
forms in brain parenchyma and amyloid plaque would be
informative.
8. Conclusion
The critical observations considered in this review are that die-
tary saturated fats and cholesterol cause BBB dysfunction, resulting
in the blood-to-brain delivery of apo B lipoprotein-Ab. In some
individuals, dietary-induced disturbances in BBB integrity may be
the initiating event for AD. If cerebrovascular disturbances are cen-
tral to AD aetiology and progression, then considering strategies to
positively influence integrity is a therapeutic priority. Presently,
drug strategies used to treat AD are focussed on maintaining
cell-cell communication rather than cerebrovascular function.
Some, but not all, clinical studies suggest that statins may re-
duce AD risk and progression [190–192] although the mechanisms
for this putative effect are unclear. Relevant to the focus of this re-
view, possibilities include reduced TRL-Ab secretion; enhanced
clearance from blood of TRL-remnants containing Ab; maintenance
of BBB function and anti-inflammatory properties. Fibrates can
profoundly reduce TRL-secretion, but their efficacy in the context
of BBB function and AD risk has not been considered.
Understanding the mechanisms by which dietary fats influence
AD risk reinforces and substantiates the good nutrition public
health strategies for prevention of disease. In a treatment context
there may also be substantial value in knowing these mechanisms.
However, developing nutritional/lifestyle or drugs which poten-
tially may confer cerebrovascular benefit is not likely to be useful
unless environmental and endogenous cerebrovascular ‘insults’
are synergistically considered.
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General Discussion and Future Studies 
 
General Discussion and Conclusion 
 
 An emerging body of evidence is consistent with the hypothesis that dietary fats 
influence AD risk (Engelhart et al. 2002; Morris et al. 2003; Solfrizzi et al. 2009), but 
less clear is the mechanisms by which this occurs. Alzheimer’s is an inflammatory 
disorder, many consider in response to fibrillar formation and extracellular deposition of 
Aβ (Duyckaerts et al. 2009; Joachim et al. 1988a; Selkoe 2002). Alternatively, 
amyloidosis could notionally be a secondary phenomenon to inflammation, because 
some studies suggest that cerebrovascular disturbances precede amyloid plaque 
formation (Cullen 1997; Ellis et al. 1996; Itagaki et al. 1989). Hence, dietary fats may 
influence AD risk by either modulating Aβ metabolism, or via Aβ independent 
pathways. Studies included in this thesis explore these two possibilities taking into 
consideration; (i) the substantial affinity of Aβ for lipids and its ordinary metabolism as 
an apolipoprotein; (ii) evidence that Aβ has potent vasoactive properties and (iii) studies 
which show that dietary fats modulate Aβ biogenesis and secretion. 
 
 In Chapter 3, the study demonstrated the significant colocalization of plasma-
derived apo B lipoprotein and cerebral amyloid plaques in an established AD model 
animal. The data provides the evidence of the severe breakdown of BBB which lead to 
the blood-to-brain delivery of peripheral lipoprotein-Aβ and its contribution toward 
cerebral amyloidosis. Recent studies provide accumulating evidence that dietary fats 
significantly influence cerebrovascular integrity and as a consequence altered Aβ 
kinetics across the BBB (Ghribi et al. 2006; Takechi et al. 2009). In Chapter 4 and 5, it 
has been shown that chronic ingestion of saturated fats or cholesterol appears to result 
in BBB dysfunction and exaggerated delivery from blood-to-brain of peripheral Aβ 
associated with lipoproteins of intestinal and hepatic origin. Interestingly, the pattern of 
saturated fat/cholesterol induced cerebrovascular disturbances in otherwise normal 
wild-type animal strains is analogous to established models of AD genetically modified 
to overproduce Aβ, consistent with a causal association. Saturated fats and cholesterol 
may exacerbate Aβ induced cerebrovascular disturbances by enhancing exposure of 
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vessels to circulating Aβ. However, presently there is no evidence to support this 
contention. Rather, SFA and cholesterol appear to more broadly compromise BBB 
integrity with the consequence of plasma protein leakage into brain, including 
lipoprotein associated Aβ. The latter findings are consistent with the concept that AD is 
a dietary-fat induced phenotype of vascular dementia, reflecting the extraordinary 
entrapment of peripherally derived lipoproteins endogenously enriched in Aβ. Rather 
than being the initiating trigger for inflammation in AD, accumulation of extracellular 
lipoprotein-Aβ may be a secondary amplifier of dietary induced inflammation, or 
possibly, simply be consequential. Clearly, delineating the mechanisms by which 
dietary fats increase AD risk may be informative in developing new strategies for 
prevention and treatment of AD. 
 
 
Limitations of study 
 
 Even though the wild-type and transgenic animal models utilized are established 
and widely used, clinical studies confirming the key findings are warranted. Mice are 
herbivorous, hence tolerance and susceptibility to diets enriched with saturated fats or 
cholesterol may differ from humans.  
 
 There are metabolic differences between mammalian species and indeed even 
between strains of mice. Subtle differences in protein expression may be responsible for 
substantial differences aetiology, disease progression or pathology. Hence the findings 
in mice presented in this thesis must be interpreted with caution when considering their 
relevance to human. Studies in other mammalian species would also be helpful in 
considering generalisability of the findings.  
 
 Immunological based methods were used to quantitate key proteins such as Aβ 
and to determine their distribution in tissues and indeed within cells. One 
methodological limitation relevant to this study was the potential confounding effects of 
lipids that may bind tightly to proteins of interest. Lipids may interfere with binding of 
antibodies with protein epitopes consequently underestimating protein abundance or 
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distribution (James and Mamo 2005; Yanagisawa et al. 1997). In published article 4, 
there was no difference in the plasma concentration of Aβ between mice fed low-fat or 
saturated-fatty acids.  The findings suggest that dietary saturated-fat induced 
disturbances in BBB integrity occur independently of change in plasma Aβ 
concentration However, as discussed in chapter 5, significant changes in plasma 
lipoprotein Aβ as a consequence of SFA feeding may not have been detected because of 
the confounding effects of lipids. In some instances, lipids can be separated from the 
protein of interest, however this often requires complex procedures (Mamo et al. 2008).  
 
 
Future studies 
 
 This thesis presented a quality series of evidence to investigate the partial 
mechanisms of the link between dietary fat and AD risk. Moreover, the studies for the 
first time demonstrated the effects of diet on BBB integrity. These data may be 
informative for future AD research and may contribute to the development of strategy 
for AD prevention and treatment. The data presented in this thesis have suggested that 
the dietary saturated fatty acids and cholesterol may increase the AD risk or exacerbate 
its pathology by causing the dysfunction of BBB which may lead to the blood-to-brain 
leakage of plasma neurotoxic and neuroinflammatory agents including TRL-Aβ. The 
findings are hypothesis generating and substantially more research is required to 
delineate the role of dietary fats and nutrition per se in AD risk. Some key areas of 
interest would be to explore the possible reversibility of SFA/cholesterol induced 
disturbances in BBB function. Moreover, the interactive effects of diet with genetic 
dyslipidemia or with lipid lowering drugs deserve attention. Several abnormal mental 
and physical conditions including head injury, stroke and mental stress are reported as a 
risk factor for BBB dysfunction (Ghabriel et al. ; Sandoval and Witt 2008). In some 
instances these conditions may be transient which could be informative in comparison 
to chronic dietary induced disturbances. 
 
 Perhaps of most interest is an accumulating body of evidence which shows that 
biological agents with anti-oxidative and anti-inflammatory properties maintain and in 
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some instances restore vascular function (Allen and Bayraktutan 2009; Kuhlmann et al. 
2008). Investigating the role of such agents on cerebrovascular integrity may be pivotal 
for prevention and treatment of AD and other vascular forms of dementia.  
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and secretion is the lipidation of apo B within the endoplasmic reticulum and Golgi 
apparatus. In this study, the 3-D immunofluorescent colocalization analysis technique 
described in Chapter 2 was used to determine the colocalization of Aβ and apo B within 
the Golgi compartment of enterocytes. 
 
 Double immunofluorescent staining demonstrated that both Aβ and apo B in the 
enterocytes were located within the Golgi apparatus that is located in the perinuclear 
region of the cells. Immunoreactivity of apo B and Aβ was also observed in the 
basolateral region of enterocytes and within the lacteals. 3-D colocalization analysis 
showed substantial colocalization of Aβ and apo B including in lacteals, consistent with 
the concept that Aβ is secreted as a nascent chylomicron. However, there was no 
evidence that relative abundance of the two proteins were correlated 
 
 The finding of this study is consistent with the notion that Aβ is synthesized and 
secreted into the circulation as apoprotein of chylomicrons via similar pathway to the 
chylomicron metabolism, that supports the hypothesis of this thesis.  
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Appendix C 
Conference Abstracts 
 
Abstracts presented at international conferences during my candidacy are listed, and the 
abstracts are attached. 
 
2008 International Symposium on Chylomicron in Disease, Alberta, Canada 
 Takechi R, Galloway S, Pallebage-Gamarallage M, Johnsen R, Mamo J. 
“Immunohistological analysis of intestinal apolipoprotein B and its 3-
dimensional colocalization with Golgi apparatus.” 
 * awarded Young Scholar Travel Award 
 
2009 The 41st Annual Scientific Meeting of Japan Atherosclerosis Society, 
Yamaguchi, Japan 
 Takechi R, Galloway S, Pallebage-Gamarallage M, Wellington C, Johnsen 
R, Mamo J. “New insight of Alzheimer’s disease-high fat diet link.” 
 *awarded Young Tainee Travel Grant 
 
2009 Annual Scientific Meeting of Australian Atherosclerosis Society 2009, 
Victoria, Australia 
 Takechi R, Galloway S, Pallebage-Gamarallage M, Mamo J. “Differential 
effects of dietary fatty acids on the cerebral distribution of plasma derived 
apo B lipoproteins with amyloid-β.” 
 *awarded Best Poster Presentation Award 
 
2009 International Congress on Vascular Dementia 2009, Barcelona, Spain 
 Takechi R, Galloway S, Pallebage-Gamarallage M, Wellington C, Johnsen 
R, Mamo J. “Chronic ingestion of saturated fats induce the disruption of 
BBB and increase blood-to-brain delivery of lipoprotein Aβ.” 
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IMMUNOHISTOLOGICAL ANALYSIS OF INTESTINAL APOLIPOPROTEIN B AND 
ITS 3-DIMENSIONAL COLOCALIZATION WITH GOLGI APPARATUS 
 
Takechi R, Galloway S Johnsen R and Mamo J. 
Australian Technology Network, Centre for Metabolic Fitness and the School of Public 
Health, Curtin University of Technology, Western Australia. 
 
Background: The assembly and secretion of chylomicrons has been investigated in cell 
culture and animal model systems and extrapolations have been made from studies 
detailing hepatic lipoprotein biosynthesis. Chylomicrons are synthesized continuously 
even with prolonged absence of dietary lipids. On the other hand, some dietary fats 
appear to regulate chylomicron secretion. Apolipoprotein B48 (apo B48) requires 
lipidation to generate a nascent primordial lipoprotein a process which is probably 
completed within the endoplasmic reticulum (ER) and Golgi apparatus. In this study, 
we have investigated chylomicron assembly and secretion utilizing novel three-
dimensional immunohistological methodologies.  
 
Results 1: Distribution of apo B in mouse small intestine  
The distribution of apo B in the small intestine was determined by immunofluorescent 
microscopy. Substantial immunoreactivity was seen within the perinuclear region of 
enterocytes. There was also significant apo B staining within lacteals, consistent with 
secretion into lymphatics.  
Results 2: Colocalization of apo B and Golgi 
Three dimensional immunofluorescent colocalization studies were done utilizing 
ApoTome based microscopy techniques (Zeiss). Within enterocytes, apo B strongly co-
localized with Golgi 75.2±8.5% consistent with the purported assembly of 
chylomicrons. 
 
Conclusion: Immunofluorescence microscopy can provide novel insight into small 
intestinal chylomicron homeostasis. 
 
 
Figure 1                                  Figure 2                             Figure 3 
 
Figure 1. Distribution of small intestinal apo B. Significant staining of apo B was 
observed within the enterocytes. Apo B staining was also observed in the lacteals. 
Figure 2. Enterocytic apo B. Strong staining of apo B was observed in the perinuclear 
areas of enterocytes. 
Figure 3. 3-dimensional colocalization of apo B and Golgi apparatus. The figure 
represents the 3-dimensional colocalization of Golgi and apo B within enterocytes. Of 
total enterocytic apo B, 75% was associated within the ER/Golgi apparatus. 
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Saturated fats disrupt blood-brain barrier integrity resulting in blood-to-
brain delivery of lipoprotein-amyloid-β; Implications for Alzheimer’s 
disease risk. 
 
Ryusuke Takechi1,2, Susan Galloway1, Menuka M Pallebage-Gamarallage1, 
Cheryl L Wellington3, Russell D Johnsen4,5, Satvinder Dhaliwal1, John CL 
Mamo1,2 
1School of Public Health, Faculty of Health Science, Curtin University of 
Technology, WA, Australia 
2Centre for Metabolic Fitness, Australian Technology Network, WA, Australia 
3Department of Pathology and Laboratory Medicie, University of British 
Columbia, BC, Canada 
4Centre for Neuromuscular and Neurological Disorders, University of Western 
Australia, WA, Australia 
5The Australian Neuromuscular Research Institute, QEII Medical Research 
Centre, WA, Australia 
 
School of Public Health, Faculty of Health Science, Curtin University of 
Technology, Kent st, Bentley, WA, 6128 Australia. E-mail: 
J.Mamo@Curtin.edu.au  
Ph: +61-8-92667232, Fax: +61-8-92662958 
 
Some dietary fats are a risk factor for Alzheimer’s disease (AD) but the 
mechanisms for this association are presently unknown. A major 
neuropathological marker of AD is amyloid-β (Aβ) deposition in the 
parenchyma of brain. However the origin of this protein still remains 
controversial. In this study we show in wild-type mice that chronic 
ingestion of saturated fats (SFA) results in blood-brain barrier (BBB) 
dysfunction and significant leakage into brain of dietary-derived 
lipoproteins enriched in Aβ. In contrast, chronic ingestion of 
monounsaturated or polyunsaturated fatty acids had no detrimental effect 
on BBB integrity. Utilizing highly sensitive 3-dimenisional immuno-
microscopy, we also show in a murine model of AD, a positive association 
of intestinal and hepatic derived apolipoprotein B lipoproteins with 
cerebral amyloid plaque. Collectively, the findings of this study provide a 
plausible explanation of how dietary fats influence AD risk. Ingestion of 
saturated fats may enhance peripheral delivery to brain of circulating 
lipoprotein-Aβ and exacerbate the amyloidogenic cascade. 
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DIFFERENTIAL EFFECTS OF DIETARY FATTY ACIDS ON THE CEREBRAL 
DISTRIBUTION OF PLASMA DERIVED APO B LIPOPROTEINS WITH AMYLOID-β   
 
Takechi R
1,5,6
, Galloway S
1,5,6
, Pallebage-Gamarallage MS
1,5,6
, Wellington CL
2
, Johnsen RD
3,4
, 
Dhaliwal SS
1,5,6
, Mamo JC
1,5,6
* 
1School of Public Health, Faculty of Health Science, Curtin University of Technology, Bentley, 
WA, Australia. 2Department of Pathology and Laboratory Medicine, University of British 
Columbia, Vancouver, BC, Canada. 3Centre for Neuromuscular and Neurological Disorders, 
University of Western Australia, Nedlands, WA, Australia. 4The Australian Neuromuscular 
Research Institute, Nedlands, WA, Australia. 5The Australian Technology Network, Centre for 
Metabolic Fitness, Perth, WA, Australia. 6The Curtin Health Innovation Research Institute 
 
Some dietary fats are a risk factor for Alzheimer’s disease (AD) but the mechanisms for this 
association are unknown. In a murine model we show that chronic ingestion of saturated fats 
(SFA) results in blood-brain barrier (BBB) dysfunction and delivery into brain of apo B 
lipoproteins that are endogenously enriched in amyloid-β (Aβ). Apo B delivery was greatest in 
regions of brain with greater capillary density. Consistent with BBB dysfunction, pPlasma S100B 
(a marker of brain-to-blood leakage) was doubled in SFA mice and expression of the endothelial 
tight junction protein occludin was reduced. Utilizing sensitive 3-dimenisional immuno-
microscopy, we also show that the cerebral distribution and colocalization of Aβ with apo B 
lipoproteins in SFA fed mice, is similar to that found in APP/PS1 amyloid transgenic mice, an 
established murine model of AD. Moreover, there was a strong positive association of plasma 
derived apo B lipoproteins with cerebral Aβ deposits. Ongoing studies suggest that the 
deterioration in BBB function in SFA fed mice may be reversible and that some lipid modulating 
agents may confer a level of protection. Collectively, the findings of this study provide a 
plausible explanation of how dietary fats may influence AD risk. Ingestion of SFA could enhance 
peripheral delivery to brain of circulating lipoprotein-Aβ and exacerbate the amyloidogenic 
cascade.  
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Chronic ingestion of saturated fats induce the disruption of BBB and 
increase blood-to-brain delivery of lipoprotein-Aß 
Ryusuke Takechi1,2, Susan Galloway1, Menuka Pallebage-Gamarallage1, Cheryl 
Wellington3, Russell Johnsen4,5, John Mamo1,2 
1School of Public Health, Curtin Health Innovation Research Institute, Curtin 
University of Technology, Australia 
2Centre for Metabolic Fitness, Australian Technology Network, Australia 
3Department of Pathology and Laboratory Medicine, University of British 
Columbia, Canada, 
4Centre for Neuromuscular and Neurological Disorders, University of Western 
Australia, Australia 
5The Australian Neuromuscular Research Institute, Australia 
Background: Saturated fats (SFA) and cholesterol are risk factors for 
Alzheimerʼs disease (AD), but the mechanisms for this effect are not clear. We 
reported that dietary SFA stimulate synthesis and secretion of lipoprotein bound 
amyloid-ß (Aß) from the small intestine and in clinical studies found that AD 
subjects have exaggerated plasma Aß bound to apolipoprotein (apo) B 
containing lipoproteins. It is our hypothesis that dietary induced elevations in 
plasma Aß compromise BBB integrity and exacerbate amyloidosis.  
Aim:  to investigate in wild-type mice the differential effects of dietary fatty acids 
on BBB function. 
Methods: C57BL/6J mice were fed chow enriched in either low fat (LF control) 
SFA, monounsaturates (MUFA) or polyunsaturates (PUFA) for 3 months. BBB 
integrity was assessed by  immunofluorescence  microscopy and included 
cerebral extravasation apo B lipoproteins naturally enriched in Aß as well as 
IgG. Expression of the endothelial tight junction protein occluding was 
measured and plasma S100B was used as a marker of brain-to-blood leakage. 
Results: SFA fed mice had significant cerebral extravasation of IgG and apo B 
containing lipoproteins. Occludin expression was substantially attenuated in 
SFA mice and plasma levels of S100B increased 2-fold. Cerebral apo B 
colocalized with Aß immunoreactivity. Mice fed MUFA, PUFA or LF diets 
showed no cerebrovascular abnormalities.  
Conclusion: Our findings are consistent with the hypothesis that dietary fats 
influence AD risk by modulating BBB function. 
 
 
